Clinical trials: Antiepileptic Drugs
Epilepsy, Aging Disorder
ZEBinix® Retention Rate in Epilepsy in Elderly Patients
The incidence of provoked and unprovoked seizures is known to increase with advancing age. Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs) that have been developed in the last ten years…
- Conditions
- Epilepsy, Aging Disorder, Aging, Epilepsy; Seizure
- Trial name
- ZEBRE (NCT04221282)
- Testing
- Zebinix
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Saint Joseph Saint Luc de Lyon
Neuropathic Pain, Vitamin B 12 Deficiency
Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Neuropathic Pain
Neuropathic pain (NeP) is a disorder of the nervous system resulting from altered mechanisms operating at the peripheral nervous system, spinal cord and supraspinal levels and is defined by the International Association for the…
- Trial name
- NCT07013318
- Where
- Turkey (Türkiye)
- Volunteers
- 96 people
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Epilepsy, Seizures
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
The purpose of this study is to compare the effectiveness and safety of topiramate to standard antiepileptic drugs in children and adults with newly diagnosed epilepsy.
- Trial name
- NCT00236717
- Testing
- Topiramate; Carbamazepine; Valproate
- Volunteers
- 865 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Seizures
A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures
The purpose of this study is to evaluate the efficacy and safety of topiramate as an add-on therapy in epilepsy patients with uncontrolled primary generalized tonic-clonic seizures, who are taking 1 or 2 standard antiepileptic…
- Trial name
- NCT00236418
- Testing
- topiramate
- Volunteers
- 80 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Generalized Tonic-clonic Seizures
A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures
To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged ≥4 to <16 years with uncontrolled Generalized Tonic-Clonic…
- Trial name
- NCT01292837
- Testing
- Levetiracetam
- Where
- 26 sites in Japan
- Volunteers
- 13 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy, Seizure
Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy
The purpose of this study is to determine if antiepileptic drugs (AEDs) differ in their neurodevelopmental effects. Specifically, do the children of the women with epilepsy differ in their behavioral and cognitive development…
- Conditions
- Epilepsy, Seizure, Cognition Disorders
- Trial name
- NCT00021866
- Testing
- Differential Abilities Scale, Neuropsychological Testing
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 331 people
- Sponsor
- Emory University
Partial Onset Seizures
Phase II BGG492 Capsule Extension for Partial Epilepsy
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
- Trial name
- NCT01338805
- Testing
- BGG492
- Where
- 16 sites in United States, Germany and 4 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Brain Tumor
Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
The purpose of this research study is to determine if sunitinib can get past the blood-brain barrier and into the brain tumor. Sunitinib has shown promising results in treating other cancers and works by blocking blood flow to…
- Trial name
- NCT00864864
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Glioblastoma
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
PTK is an investigational new drug that has been shown in early laboratory studies to prevent the formation of new blood vessels that allow the tumor to grow.
- Trial name
- NCT00385853
- Testing
- PTK787/ZK 222584, Temozolomide, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Epilepsy
Population Pharmacokinetics of Antiepileptic in Pediatrics
The purpose of this study is to develop population pharmacokinetic models for antiepileptic drugs in a pediatric population. The interest of these models is multiple: describe the pharmacokinetics of these molecules in children…
- Trial name
- EPIPOP (NCT03196466)
- Testing
- Valproic acid, carbamazepine, phenobarbital
- Where
- France
- Volunteers
- 753 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Epilepsy
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a…
- Trial name
- NCT01405508
- Testing
- Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion
- Where
- 17 sites in United States, Czechia and 2 more
- Volunteers
- 105 people
- Sponsor
- UCB Pharma
Autism, Developmental Delay
Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine
This study is investigating the neurodevelopmental effects of prenatal exposure to lamotrigine (LTG), sodium valproate (VPA), or carbamazepine (CBZ) monotherapies. The hypotheses to be tested include: 1.
- Conditions
- Autism, Developmental Delay, Birth Defects
- Trial name
- NCT01097720
- Where
- United States
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Refractory Status Epilepticus
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED)…
- Trial name
- NCT05814523
- Testing
- Ganaxolone, Standard of care
- Where
- 52 sites in Austria, Belgium and 14 more
- Sponsor
- Marinus Pharmaceuticals
Bio-equivalence Study, Fed Conditions
Fed Bioequivalence Study of CBZ Formulations
Controlled release Carbamazepine (CBZ) is a antiepileptic, antineuralgic and mood stabilizer drug. The CR formulation of CBZ is slowly absorbed and the elimination half life varies with time due to metabolism autoinduction.
- Trial name
- NCT02132897
- Testing
- Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose, Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
- Where
- Uruguay
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Center for Clinical Pharmacology Research Bdbeq S.A.
Epilepsy
Role of Clinical Pharmacists in Epilepsy Management
Clinical pharmacists have an important role in inter-professional healthcare collaboration for epilepsy management. However, the pharmacy practices of managing epilepsy are still limited in Vietnam, deterring pharmacists from…
- Trial name
- NCT04967326
- Testing
- Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)
- Volunteers
- 141 people
- Sponsor
- Gia Dinh People Hospital
Essential Tremor, Movement Disorders
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
The purpose of this study is to evaluate the effectiveness, safety and tolerability of carisbamate treatment for the signs, symptoms, and impairment associated with Essential Tremor (ET) compared to placebo treatment.
- Trial name
- NCT00524056
- Testing
- Carisbamate
- Volunteers
- 62 people
- Sponsor
- SK Life Science, Inc.
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
The purpose of this study is to evaluate the effectiveness and safety of the novel compound RWJ-333369 in reducing the frequency of seizures in patients with epilepsy.
- Trial name
- NCT00210522
- Testing
- RWJ 333369
- Volunteers
- 421 people
- Sponsor
- SK Life Science, Inc.